The Clinical Challenges of Multiple Sclerosis: Managed Care and Specialty Pharmacist Perspectives
Supported by an educational grant from Teva Neuroscience.
Provided by The University of Tennessee College of Pharmacy, in cooperation with ASiM.
Multiple sclerosis (MS) is a complex neurologic disease with both medical and economic challenges that affect management decision making. Outlining recent advances in pathophysiology and immunopathology, practice guidelines, and practical applications of current and future treatments for patients with MS is an essential part of directing optimal care. With the introduction of treatments designed to change the natural disease course in patients with MS, the economic burden of the disease needs to be understood and carefully navigated. Economic evaluations, which analyze the burden of MS on society and the cost-effectiveness of new disease modifying agents, stress that the economic burden of MS should be viewed in a global perspective, and that new treatments offer an opportunity to reduce the burden of the disease in the long-term. Further rigorous economic evaluations that focus on the comparison of different available alternatives are necessary for current and emerging MS therapies. Balancing cost-effective treatment with current guidelines and optimal therapy can be a challenge to pharmacists who are practicing in the managed care setting. In order to perform effectively, managed care and specialty pharmacists need a sense of the economic value of MS drug therapies for formulary selection and/or placement and optimizing patient care. This archived webcast discusses how to translate this wealth of information into clinical practice to improve patient and pharmacoeconomic outcomes.
This archived webcast will provide managed care and specialty pharmacists with up-to-date information on pharmaco- and socioeconomic issues in MS therapy, how to promote patient adherence, and the specialty and managed care implications of treating MS to improve patient outcomes.
This activity is designed for managed care and specialty pharmacists. No prerequisites required.
The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity. At the conclusion of this activity, the participant should be able to:
- DISCUSS current and emerging therapies, their safety and efficacy, mechanisms of action and the importance of treating early to slow disease progression.
- COMPARE emerging and currently available agents for reducing disability and relapse rates in MS and define their appropriate place in therapy taking into consideration safety.
- IDENTIFY managed care considerations for assuring optimal multiple sclerosis treatment.
The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education to provide continuing education for pharmacists.
Credit Designation Statement
The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this knowledge-based program will provide a statement for 1.5 contact hours of credit (0.15 CEUs) and will be available at the completion of the activity. Successful completion includes participating in the activity, completing a self-assessment instrument with a score of at least 70%, and completing an evaluation instrument. If you score less than 70% on the self-assessment instrument, you will be allowed to complete the examination 2 additional times. ACPE Program Number 0064-0000-12-213-H01-P. Your CE credits will also be submitted electronically to NABP. Pharmacists or pharmacy technicians with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website (www.nabp.net/programs/cpe-monitor/cpe-monitor-service) or contact NABP Customer Service: email@example.com or telephone 847-391-4406.
Type of Activity: Knowledge
Published: February 25, 2013
Expires: February 25, 2014
There is no fee for this educational activity.
Estimated time to complete activity
HOW TO EARN CREDIT
Please complete the post-test questions and activity evaluation online at: www.powerpak.com (a username and password are required to access your account). Upon passing the exam with a score of 70% or better, you can print out your statement of credit immediately. You can also view your test history at any time and print out duplicate statements from the Web site.
Full disclosure policy affecting cPe activities
As an accredited provider by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of The University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Course Directors and Participating Faculty reported the following:
Jacqueline Bainbridge, PharmD, FCCP (Co-Course Director)
Skaggs School of Pharmacy and Pharmaceutical Sciences
Department of Clinical Pharmacy and Department of Neurology
University of Colorado Anschutz Medical Campus
Dr Bainbridge reports receiving grants/research support from the National Institutes of Health; and reports serving on the speakers’ bureau for Teva and UCB S.A.
Sheldon J. Rich, RPh, PhD (Co-Course Director)
President, SJR Associates, LLC
Adjunct Clinical Assistant Professor
University of Michigan
Adjunct Assistant Professor
Wayne State University
Palm Beach Gardens, Florida
Dr Rich reports having no relevant financial or advisory relationships with corporate organizations related to this activity.
Augusto Miravalle, MD
Assistant Professor of Neurology
Department of Neurology
University of Colorado
Dr Miravalle reports serving as an consultant for Accordia, Bayer HealthCare, Biogen Idec, Clear View, EMD Serono, Inc, Questcor Pharmaceuticals, and Teva Neuroscience, Inc; and reports receiving grants/research support from the Accelerated Cure Project for MS, Biogen Idec, F. Hoffmann-La Roche Ltd, Teva, and XenoPort, Inc.
Ellen Whipple Guthrie, PharmD
Clinical Assistant Professor
University of Georgia College of Pharmacy
Multiple Sclerosis Foundation
Fort Lauderdale, Florida
Dr Whipple Guthrie reports serving as a contractor for The Medical Affairs Company; and reports holding stock in Teva.
Susanne Batesko, RN, BSN, Michele Salernitano, Robin Carrino, and the clinical reviewers, planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices to disclose in relation to this activity. We are committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.
OFF-LABEL PRODUCT DISCUSSION
In accordance with ACPE Criteria for Quality, the audience is advised that authors of this CPE activity may include reference(s) to unlabeled, unapproved, or investigational uses of therapeutic agents or biomedical devices. The authors will inform the reader of when they discuss or reference an unapproved, unlabeled, or investigational use of therapeutic agent or biomedical device.
The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of The University of Tennessee College of Pharmacy name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.
A participant, sponsor, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity sponsored or cosponsored by The University of Tennessee College of Pharmacy may contact the Associate Dean for Continuing Education in writing at firstname.lastname@example.org. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.
REQUIRED COMPUTER HARDWARE/SOFTWARE
Please ensure the computer you plan to use meets the following requirements:
- Operating System: Windows or Macintosh
- Media Viewing Requirements: Flash Player or Adobe Reader
- Supported Browsers: Microsoft Internet Explorer, Firefox, Google Chrome, Safari and Opera
- Most importantly, an internet connection